About Us
Corporate Overview
BromAc® was discovered by our group of clinicians and scientists, who specialise in treating patients with advanced cancers of the peritoneum. We were screening for possible therapies for rare disease of the appendix, pseudomyxoma peritonei. Our laboratory research work lead to the discovery of our drug BromAc®, which removes mucin from cancer cells and sensitises cancer cells to chemotherapy agents.
Established in 2017 by Professor David Morris (Surgical Oncologist, Department of Surgery, St George Hospital & University of New South Wales) and the Herszberg Family, Mucpharm has grown to become a specialised company focused on the treatment of mucin-containing and secreting cancers and other diseases involving glycoproteins. Since then, Mucpharm has developed global collaborative partnerships, well supported scientifically and funded by aligned organisations and investors.
Program Lead Scientists
Dr Javed Akhter Dr Ahmed Mekkawy
Laboratory Manager, Microbiology Pre-Clinical Research and Immunology
Dr Krishna Pillai Dr Mathew Eapen
Organic Chemist, Pharmacologist Respiratory Research
Anant Solanki
Analytical Chemist
Mucpharm collaborates with a number of scientific teams in Australia, United Kingdom, United States, Brazil and Europe to develop the preclinical programs in infectious diseases and oncology.
Management Committee
Prof David L Morris MBChB FRCS FRCSE MD PhD FRACS Myer Herszberg
CEO, Co-Founder Chairman, Co-Founder
Mark Lawrence Dr Richard Mollard PhD, MBA
Director Chief Scientific & Commercialisation Officer
Sarah Valle BMedSc, BN Steven Davis
Regulatory and Clinical Program Board Advisor - US and EU relations
Mucpharm’s Scientific Advisory Team includes experts in surgical and medical oncology, intensive care, infectious diseases, respiratory physicians and consultants with preclinical and clinical pharmaceutical development backgrounds. We are grateful that we have a broad team of highly regarded international experts and patient advisory groups supporting us through our development program.